Ensemble Therapeutics to highlight IL-17A inhibitor Ensemblin at 245th ACS National Meeting

Apr 2 2013

Ensemble Therapeutics today announced that preclinical data showing the advantages of its Ensemblins, novel macrocyclic compounds against challenging drug targets, will be presented at the 245th American Chemical Society (ACS) National Meeting being held April 7-11, 2013 in New Orleans, LA. In particular, the presentation will highlight Ensemble's first-in-class, orally active small molecule antagonists of Interleukin-17 (IL-17), a cytokine implicated in multiple inflammatory and autoimmune diseases, and present preclinical data on the oral efficacy and anti-inflammatory effects of the company's IL-17A inhibitor Ensemblin.

“Ensemble's DNA-programmed chemistry platform rapidly screened and identified novel, orally active small molecules against IL-17, a key pro-inflammatory cytokine known to be active in human and animal models of rheumatoid arthritis”

"Ensemble's DNA-programmed chemistry platform rapidly screened and identified novel, orally active small molecules against IL-17, a key pro-inflammatory cytokine known to be active in human and animal models of rheumatoid arthritis," said Dr. Michael D. Taylor, CEO of Ensemble Therapeutics. "Ensemble's small molecule IL-17 antagonists retain certain attractive DMPK characteristics such as extended duration of target binding — measured in hours and comparable to the IL-17 biologics currently in development -- and also desirable drug-like properties including oral bioavailability and demonstrated oral efficacy in animal models."

Oral Presentation:

• 'Macrocycles for Drug Discovery - Identification of Small Molecule Synthetic Macrocycle Antagonists of Human IL-17A", Nick K. Terrett, Ph.D. - Chief Scientific Officer, Ensemble Therapeutics, Wednesday, April 8, 2013, 2:55pmCDT, Session: Next Generation Molecules as Tools and Drugs

Ensemble will also be presenting on its first-in-class, orally active small molecule antagonists of Interleukin-17 at the CHI Drug Discovery Chemistry conference on April 16, 2013 in San Diego during the Constrained Peptides and Macrocyclics Drug Discovery session.

SOURCE Ensemble Therapeutics